Literature DB >> 9402826

Diode laser contact transscleral cyclophotocoagulation for refractory glaucoma in Asian patients.

E Y Wong1, P T Chew, C K Chee, J S Wong.   

Abstract

PURPOSE: To evaluate the effectiveness and safety of diode laser contact transscleral cyclophotocoagulation in Asian patients with refractory glaucoma by lower energy settings with an innovative probe featuring a glass ball tip that focused the laser beam onto the ciliary body.
METHODS: This prospective clinical study included consecutive Asian patients with dark irides and confirmed for glaucoma. Only one eye of each patient was treated. Diode laser contact transscleral cyclophotocoagulation treatment was performed with the center of the probe placed 1.5 mm behind the limbus. About 30 pulses of 810-mm laser radiation (power, 1.8 to 2.0 W; duration, 0.3 to 0.5 second) were applied around the eye. Patients were examined at fixed postoperative intervals. Intraocular pressure levels and postoperative complications were recorded. The relation between patient and disease characteristics, total laser energy delivered, and intraocular pressure effects were analyzed.
RESULTS: Thirty-three patients were studied, with a mean follow-up period of 9.4 months. An average 56% of patients showed a 30% or greater drop in intraocular pressure. About 38% of patients achieved sustained intraocular pressure lowering to below 22 mm Hg at 18 months. Complications were few and included transient hypotony and iritis.
CONCLUSIONS: In Asian patients with refractory glaucoma or painful glaucomatous eyes with poor visual acuity (defined for this study as worse than 20/200), low-energy-setting diode laser contact transscleral cyclophotocoagulation by means of the glass ball probe is relatively effective and safe.

Entities:  

Mesh:

Year:  1997        PMID: 9402826     DOI: 10.1016/s0002-9394(14)71697-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

1.  Long term results of diode laser cycloablation in complex glaucoma using the Zeiss Visulas II system.

Authors:  S Ataullah; S Biswas; P H Artes; E O'Donoghue; A E A Ridgway; A F Spencer
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

2.  Is cyclophotocoagulation an option in the management of glaucoma secondary to Fuchs' uveitis syndrome?

Authors:  Bogomil Voykov; Christoph Deuter; Manfred Zierhut; Martin Alexander Leitritz; Emmanuella Guenova; Emmanuella Guenova-Hötzenecker; Deshka Doycheva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-05       Impact factor: 3.117

3.  Retrospective review on the outcome and safety of transscleral diode laser cyclophotocoagulation in refractory glaucoma in Chinese patients.

Authors:  Janice J C Cheung; Kenneth K W Li; Samuela W K Tang
Journal:  Int Ophthalmol       Date:  2017-12-11       Impact factor: 2.031

4.  Transscleral diode laser cyclophotocoagulation for the treatment of refractory glaucoma secondary to inflammatory eye diseases.

Authors:  T Schlote; M Derse; M Zierhut
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

5.  Intermediate results of phaco-endocycloplasty in an exclusive cohort of angle closure glaucoma: potential for change.

Authors:  Vanita Pathak-Ray
Journal:  Int Ophthalmol       Date:  2019-01-03       Impact factor: 2.031

6.  A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma.

Authors:  C C Murphy; C A M Burnett; P G D Spry; D C Broadway; J P Diamond
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

7.  Cyclophotocoagulation and cyclocryocoagulation as primary surgical procedures for open-angle glaucoma.

Authors:  Isabel Gorsler; Hagen Thieme; Christian Meltendorf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-04       Impact factor: 3.117

8.  Transscleral diode laser cyclophotocoagulation as primary and secondary surgical treatment in primary open-angle and pseudoexfoliatve glaucoma. Long-term clinical outcomes.

Authors:  Matthias Grueb; Jens Martin Rohrbach; Karl Ulrich Bartz-Schmidt; Torsten Schlote
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-21       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.